Proposed Section Structure
This article is organized to match the clinical and translational importance of the study: clinical background and unmet need; study design and biomarker rationale; key results; mechanistic and clinical interpretation; limitations and implications for practice; and a concise summary with funding and references.
Highlights
VWF antigen, VWF activity, and factor VIII activity were significantly higher in patients with chronic graft-versus-host disease than in allogeneic transplant recipients without cGvHD.
The highest biomarker levels were seen in active cGvHD, and longitudinal follow-up showed declining levels with remission but persistent elevation in ongoing active disease.
Higher VWF levels were linked to liver and oral cGvHD, while lower albumin emerged as the strongest multivariable predictor of elevated VWF measurements.
ROC analysis suggested moderate diagnostic utility for early cGvHD, with thresholds of VWF:Ag above 246.3% and VWF:Ac above 271.4%.
Background
Chronic graft-versus-host disease remains one of the most consequential long-term complications after allogeneic hematopoietic stem cell transplantation. It contributes substantially to late nonrelapse morbidity, impaired quality of life, prolonged immunosuppressive exposure, infectious risk, and mortality. Clinically, cGvHD is heterogeneous: it can involve the skin, mouth, eyes, liver, lungs, gastrointestinal tract, fascia, and genital tract, often with waxing and waning activity. That heterogeneity makes disease assessment difficult, especially when trying to distinguish active inflammatory disease from fixed organ damage.
For that reason, the field has long sought reliable biomarkers that could assist in diagnosis, activity assessment, prognostication, and response monitoring. Despite important work on chemokines, B-cell signaling molecules, and cellular immune signatures, no biomarker panel has yet become fully established for routine clinical use across centers.
The current study addresses a biologically plausible and clinically practical biomarker axis: von Willebrand factor and factor VIII. Both are linked to endothelial activation and systemic inflammation. VWF is released from endothelial cells and platelets, and its elevation can reflect vascular injury or inflammatory stress. Factor VIII circulates bound to VWF and often rises in inflammatory states. Because endothelial dysfunction is increasingly recognized as part of the pathobiology of transplant complications, including graft-versus-host disease, these hemostatic markers are attractive candidates for study.
Study Design and Methods
This was a prospective study including 83 patients with cGvHD and 39 allogeneic hematopoietic stem cell transplant recipients without cGvHD as comparators. The investigators measured VWF antigen (VWF:Ag), VWF activity (VWF:Ac), and factor VIII activity (FVIII:C).
The principal clinical questions were whether these laboratory parameters differ between patients with and without cGvHD, whether they track with disease activity, whether they associate with specific organ involvement, and whether they might be useful for early diagnosis. The study also included multivariate analyses to identify predictors of elevated biomarker levels and longitudinal analyses to examine whether biomarker trajectories change with remission or persistent activity.
The comparator group is an important feature. In transplant medicine, many laboratory abnormalities may reflect conditioning, infections, immune reconstitution, medications, or endothelial injury unrelated to cGvHD. Comparing cGvHD cases with transplant recipients without cGvHD therefore makes the analysis more clinically relevant than a comparison with healthy controls alone would have been.
Key Findings
Marked elevation in cGvHD
All three measured biomarkers were significantly elevated in patients with cGvHD compared with transplant recipients without cGvHD, with p values below 0.001. This suggests that the signal is not subtle. Importantly, the biomarker profile was strongest in active disease, supporting the idea that these factors may reflect ongoing pathobiology rather than merely a history of prior disease.
Among the three markers, VWF:Ag and VWF:Ac appear particularly compelling because they showed not only cross-sectional differences between groups but also associations with disease localization and diagnostic performance metrics.
Association with disease activity
The longitudinal component is one of the study’s most clinically valuable aspects. Biomarker studies often stop at a single time point, limiting practical interpretation. Here, VWF and FVIII levels declined when cGvHD went into remission and remained elevated in patients with active disease. That pattern strengthens the case for these markers as dynamic disease-monitoring tools rather than static risk correlates.
For clinicians, this is relevant because current disease assessment often relies on serial symptom review, physical examination, organ-specific testing, and sometimes imperfect distinctions between inflammatory activity and residual scarring. A blood-based biomarker that falls with remission could help contextualize borderline clinical scenarios.
Organ-specific associations
Higher VWF:Ag and VWF:Ac were associated with liver and oral cGvHD. This is an intriguing observation. Liver involvement in cGvHD may plausibly intersect with endothelial activation, systemic inflammation, and alterations in coagulation-associated proteins. The oral association is less immediately intuitive but may reflect broader inflammatory disease burden or specific mucosal-vascular interactions. These findings should be considered hypothesis-generating until validated externally, but they suggest that VWF biology may not merely reflect nonspecific illness.
Multivariable predictors
In multivariate analysis, lower albumin was the strongest predictor of higher VWF:Ag, with a model R² of 0.576, and also of higher VWF:Ac, with a model R² of 0.540. Older age, higher lactate dehydrogenase, and a greater number of affected organs were additional predictors.
This deserves careful interpretation. Albumin is often a negative acute-phase reactant and a broad marker of systemic inflammation, nutritional status, hepatic synthetic function, capillary leak, or chronic illness burden. Its strong inverse relationship with VWF measures supports the idea that elevated VWF in cGvHD is tied to inflammatory-endothelial stress rather than isolated coagulation activation.
For FVIII, systemic immunosuppressive therapy emerged as the main predictor, with a more modest model R² of 0.247. This weaker explanatory model suggests FVIII may be influenced by a broader mix of confounders, including inflammatory state, liver function, medication effects, and baseline prothrombotic biology.
Diagnostic performance for early cGvHD
The ROC analysis showed moderate discrimination for early cGvHD. A VWF:Ag threshold above 246.3% yielded an AUC of 0.733, while VWF:Ac above 271.4% produced an AUC of 0.728. These AUC values do not support use as stand-alone diagnostic tests, but they are clearly above chance and may be clinically meaningful as part of a multiparameter assessment strategy.
In biomarker development, an AUC in the 0.73 range is best viewed as promising rather than definitive. Such performance may prove useful when combined with clinical scoring, organ-specific findings, and perhaps other laboratory biomarkers. The pragmatic appeal is that VWF and FVIII assays are already available in many hospital laboratories, which could ease translation if future validation is favorable.
Clinical and Biological Interpretation
The results fit with a growing understanding of cGvHD as a disorder extending beyond alloreactive lymphocyte injury alone. Endothelial activation, tissue remodeling, fibrosis, innate immune signaling, and microvascular dysfunction increasingly appear relevant across transplant complications. VWF is stored in Weibel-Palade bodies of endothelial cells and rapidly released in response to activation or injury. Elevated VWF can therefore serve as a readout of endothelial perturbation. Factor VIII, stabilized in circulation by VWF, commonly rises in parallel during inflammatory states.
From a translational standpoint, the study suggests that endothelial-hemostatic markers may capture a dimension of cGvHD biology not fully represented by traditional immune biomarkers. This could be particularly useful in patients with multisystem disease, ongoing steroid exposure, or equivocal symptoms.
However, these same markers are also vulnerable to confounding. Infection, hepatic dysfunction, thrombotic tendency, cardiovascular disease, age, systemic inflammation, and treatment effects may all influence VWF and FVIII. The association with albumin and LDH in this study reinforces that these are not disease-specific molecules. Their value may therefore lie in disease monitoring and contextual decision support rather than diagnostic exclusivity.
Strengths of the Study
Several features improve the credibility and relevance of the findings. First, the prospective design is stronger than retrospective biomarker analyses. Second, the inclusion of transplant recipients without cGvHD provides a clinically appropriate comparison group. Third, the investigators examined both cross-sectional and longitudinal behavior, which is critical for judging whether a biomarker can be used for monitoring. Fourth, the study explored multivariable correlates and organ associations rather than presenting only unadjusted group differences.
The use of both VWF antigen and activity is also valuable. Antigen quantifies protein abundance, while activity may better reflect functional hemostatic behavior. Their concordant elevation supports a robust biological signal.
Limitations and Cautions
The study should still be interpreted as an important early validation step, not practice-changing evidence. The cohort size, while respectable for a prospective single-study biomarker analysis, remains limited for broad generalization. External validation in independent, ideally multicenter cohorts is necessary.
The abstract does not provide detailed sensitivity, specificity, confidence intervals, calibration measures, or subgroup performance across all transplant settings. Those details matter if these markers are to be used clinically. It is also unclear from the abstract how thoroughly intercurrent infections, thrombotic events, ABO effects, liver comorbidity, and other inflammatory conditions were accounted for, all of which could materially influence VWF and FVIII.
Another practical issue is specificity for cGvHD versus other post-transplant endothelial syndromes. Elevated VWF and FVIII may also occur in acute inflammatory complications, sinusoidal endothelial injury, thrombotic microangiopathy, infection, and steroid-related metabolic stress. A future biomarker strategy may need to incorporate these assays into a composite panel rather than rely on them alone.
Implications for Clinical Practice and Research
At present, VWF and FVIII should be viewed as promising investigational biomarkers. They are not ready to replace NIH consensus-based clinical assessment of cGvHD, nor can they independently establish diagnosis. Still, the study raises several practical possibilities.
First, these markers may help identify patients with biologically active disease when symptoms are subtle or mixed with chronic damage. Second, serial testing could support response assessment, especially if falling values consistently parallel clinical improvement. Third, given the association with liver and oral involvement, these assays may merit targeted study in organ-specific cGvHD phenotypes. Fourth, because VWF and FVIII are widely measurable, they may be easier to implement than highly specialized cytokine or cellular assays.
The next steps should include external validation, integration with established cGvHD severity scoring, assessment of predictive value for flare or treatment response, and head-to-head comparison with previously proposed biomarker panels such as CXCL9, ST2, matrix metalloproteinases, and B-cell activating factor-related signatures. It will also be important to define how much added value these tests provide beyond standard clinical evaluation and routine laboratory measures such as albumin and LDH.
Expert Commentary
This study is notable because it connects a familiar laboratory domain, coagulation and endothelial biology, to a difficult transplant medicine problem. The signal appears biologically coherent and clinically relevant. Yet the modest ROC performance and the likely influence of multiple confounders argue against overinterpretation. The strongest near-term role may be as an adjunctive biomarker for disease activity monitoring, particularly in longitudinal follow-up, rather than as a sole diagnostic discriminator.
For hematologists and transplant clinicians, the most actionable message is not that VWF or FVIII can diagnose cGvHD on their own, but that persistent or changing elevations may reflect a meaningful component of disease biology worth tracking in parallel with clinical status.
Conclusion
In this prospective study, VWF antigen, VWF activity, and factor VIII activity were significantly elevated in chronic graft-versus-host disease, most prominently in active disease. VWF measures were associated with liver and oral involvement, while longitudinal analyses showed decline with remission and persistence with active disease. Diagnostic performance for early cGvHD was moderate but clinically encouraging, especially for VWF:Ag and VWF:Ac. Overall, the findings support VWF and FVIII as promising, mechanistically plausible biomarkers for cGvHD diagnosis and monitoring, while underscoring the need for external validation and careful attention to specificity.
Funding and ClinicalTrials.gov
Funding information was not provided in the abstract or PubMed record cited here.
A ClinicalTrials.gov registration number was not reported in the abstract or PubMed record cited here.
References
Lelas A, Desnica L, Sabol I, Herak DC, Milos M, Kerep AZ, Vulic A, Durakovic N, Serventi-Seiwerth R, Peric Z, Vrhovac R, Pavletic SZ, Pulanic D. Von Willebrand factor and factor VIII as potential biomarkers for diagnosis and disease monitoring in chronic graft-versus-host disease. Bone Marrow Transplantation. 2026-05-19. PMID: 42156944.
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biology of Blood and Marrow Transplantation. 2015;21(3):389-401.e1.
Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, van den Brink MRM, Hansen JA, Parkman R, Miklos DB, Pavletic SZ, Ritz J, Schultz KR, Blazar BR, Abhyankar S, Wang T, Waller EK, Carpenter PA. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report From the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. 2017;23(2):211-234.
Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. New England Journal of Medicine. 2017;377(26):2565-2579.